Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
18.4(c) 18.2(c) 17.5(c) 16.7(c) 16.6(c) Last
314 053 1 040 329 1 217 951 956 304 592 669 Volume
+0.82% -1.09% -3.85% -4.57% -0.60% Change
More quotes
Financials ($)
Sales 2017 650 M
EBIT 2017 114 M
Net income 2017 -48,6 M
Debt 2017 511 M
Yield 2017 -
Sales 2018 543 M
EBIT 2018 34,5 M
Net income 2018 -87,4 M
Debt 2018 529 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,69x
EV / Sales2018 2,06x
Capitalization 589 M
More Financials
Company
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of AMAG Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMAG PHARMACEUTICALS, INC.
10/13 Antares Pharma Provides XYOSTED Regulatory Update
10/04 AMAG PHARMACEUTICALS : Appoints Tracy Palmer Berns as Chief Compliance Officer
09/29 AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer
09/14 AMAG PHARMACEUTICALS,INC. (NASDAQ : AMAG) Files An 8-K Departure of Directors or..
09/13 AMAG PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K)
09/12 AMAG PHARMACEUTICALS : Appoints Laura Williams, M.D. as Senior Vice President of..
09/08 AMAG PHARMACEUTICALS : to Present at Upcoming Investor Conferences
09/07 AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President o..
09/05 HERE’S OUR TAKE ON AMAG PHARMA : AMAG)’s sNDA Submission
09/05 AMAG PHARMACEUTICALS : to Present at Upcoming Investor Conferences
More news
Sector news : Pharmaceuticals - NEC
10/16DJALLERGAN : Loses Patent Fight in Federal Court
10/16DJDaimler Reshapes Company to Meet Challenges of Changing Industry -- Update
10/16 Miners provide foundation for FTSE while ConvaTec plummets
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 CONVATEC : slashes revenue growth outlook, shares slump
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/16Head to Head Comparison: Patheon NV $PTHN and AMAG Pharmaceuticals $AMAG  
10/10Want automatic email alerts for $AMAG $ATLS $PLZLY $APL $BXS? Subscribe to Ma.. 
10/07AMAG Pharmaceuticals, Inc. $AMAG Lifted to “Buy” at Zacks Investment Research.. 
10/04AMAG Pharmaceuticals upgraded by Zacks Investment Research to buy. $21.00 PT... 
10/04$1.25 EPS Expected for AMAG Pharmaceuticals, Inc. $AMAG This Quarter  
More tweets
Qtime:38
News from SeekingAlpha
10/02 ANTARES : Numerous Upcoming Catalysts
09/28 AMAG Pharmaceuticals (AMAG) Presents At Cantor Fitzgerald Global Healthcare C..
09/08 Premarket analyst action - healthcare
08/31 FDA accepts AMAG's application for expanded use of Feraheme; shares ahead 2% ..
08/06 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 6, 2017
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | AMAG | US00163U1060 | 4-Traders
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 23,3 $
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & Senior VP
Julie Krop Chief Medical Officer & SVP-Regulatory Affairs
Nathan McBride Chief Information Officer & Senior VP-Innovation
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.-52.01%589
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887